Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.51 |
| ▸ | SCD | O00767 | 2/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | ITK | Q08881 | 1/20 | 0.47 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.44 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2713277 | 0.87 | CREBBP (0.55) | L3MBTL1POLBTDP1CREBBPROCK2 | |
| SCHEMBL17790720 | 0.87 | ROCK2 (0.57) | L3MBTL1POLBTDP1CREBBPROCK2 | |
| SCHEMBL2726830 | 0.81 | CYP19A1 (0.63) | ROCK2 | |
| SCHEMBL30730357 | 0.79 | HSD17B10 (0.57) | L3MBTL1POLBTDP1SCDCYP11B1 | |
| SCHEMBL27364039 | 0.77 | L3MBTL1 (0.70) | L3MBTL1POLBTDP1HTTALK | |
| SCHEMBL13851465 | 0.75 | TDP1 (1.00) | L3MBTL1POLBTDP1HTT | |
| SCHEMBL27571041 | 0.75 | POLB (0.71) | L3MBTL1POLBTDP1HTTALK | |
| SCHEMBL19087151 | 0.75 | POLB (0.71) | L3MBTL1POLBTDP1HTTALK | |
| SCHEMBL13736854 | 0.75 | POLB (0.71) | L3MBTL1POLBTDP1HTTALK | |
| SCHEMBL2712751 | 0.75 | MRGPRX4 (0.49) | MEP1BMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630144-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-09-07 | — | — | EP | disclosed |
| EP-2630144-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-09-07 | — | — | EP | disclosed |
| US-9000154-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-9000154-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-9000154-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| EP-2630144-A1 | RHO KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2013-08-28 | — | — | EP | disclosed |
| US-20120270868-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270868-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270868-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| WO-2012054367-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012054367-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270868-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | L3MBTL1 3784/4885POLB 2839/4885TDP1 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.